Tumor PD-L1 membrane expression (Dako 28-8) correlated with greater efficacy; only in PD-L1+ patients, nivolumab was superior; PD-L1+ prevalence: 53–55, 38–41, and 35–37% using cutoffs of ≥1%, ≥5%, and ≥10%, respectively. Here, CD274 is linked to neoplasm.